A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader

Apweiler, 2004, UniProt: the Universal Protein knowledgebase, Nucleic Acids Res., 32, D115, 10.1093/nar/gkh131

Bacher, 2008, Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients, Blood, 111, 2527, 10.1182/blood-2007-05-091215

Barouch-Bentov, 2011, Mechanisms of drug resistance in kinases, Expert Opin. Investig. Drugs, 20, 153, 10.1517/13543784.2011.546344

Bondeson, 2015, Catalytic in vivo protein knockdown by small-molecule PROTACs, Nat. Chem. Biol., 11, 611, 10.1038/nchembio.1858

Boschelli, 2001, Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity, J. Med. Chem., 44, 3965, 10.1021/jm0102250

Bossi, 2010, Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors, Biochemistry, 49, 6813, 10.1021/bi1005514

Buckley, 2012, Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL/HIF-1alpha interaction, J. Am. Chem. Soc., 134, 4465, 10.1021/ja209924v

Carmena, 2012, The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis, Nat. Rev. Mol. Cell Biol., 13, 789, 10.1038/nrm3474

CenterWatch. (2017). FDA Approved Drugs. https://www.centerwatch.com/drug-information/fda-approved-drugs.

Deshaies, 2015, Protein degradation: prime time for PROTACs, Nat. Chem. Biol., 11, 634, 10.1038/nchembio.1887

Douglass, 2013, A comprehensive mathematical model for three-body binding equilibria, J. Am. Chem. Soc., 135, 6092, 10.1021/ja311795d

Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N. Engl. J. Med., 350, 2572, 10.1056/NEJMoa032534

Erb, 2017, Transcription control by the ENL YEATS domain in acute leukaemia, Nature, 543, 270, 10.1038/nature21688

Fischer, 2014, Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide, Nature, 512, 49, 10.1038/nature13527

Gadd, 2017, Structural basis of PROTAC cooperative recognition for selective protein degradation, Nat. Chem. Biol., 13, 514, 10.1038/nchembio.2329

Galanis, 2014, Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants, Blood, 123, 94, 10.1182/blood-2013-10-529313

Galdeano, 2014, Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities, J. Med. Chem., 57, 8657, 10.1021/jm5011258

Galkin, 2007, Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK, Proc. Natl. Acad. Sci. USA, 104, 270, 10.1073/pnas.0609412103

Han, 2017, Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15, Science, 356, 10.1126/science.aal3755

Hauser, 2008, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N. Engl. J. Med., 358, 676, 10.1056/NEJMoa0706383

Hendriks, 2014, Targeting Bruton's tyrosine kinase in B cell malignancies, Nat. Rev. Cancer, 14, 219, 10.1038/nrc3702

Ito, 2010, Identification of a primary target of thalidomide teratogenicity, Science, 327, 1345, 10.1126/science.1177319

Itoh, 2010, Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins, J. Am. Chem. Soc., 132, 5820, 10.1021/ja100691p

Karaman, 2008, A quantitative analysis of kinase inhibitor selectivity, Nat. Biotechnol., 26, 127, 10.1038/nbt1358

Kronke, 2014, Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells, Science, 343, 301, 10.1126/science.1244851

Kronke, 2015, Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS, Nature, 523, 183, 10.1038/nature14610

Lai, 2016, Modular PROTAC design for the degradation of oncogenic BCR-ABL, Angew. Chem. Int. Ed., 55, 807, 10.1002/anie.201507634

Larrue, 2016, Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells, Blood, 127, 882, 10.1182/blood-2015-05-646497

Levis, 2013, FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?, Hematol. Am. Soc. Hematol. Educ. Program, 2013, 220, 10.1182/asheducation-2013.1.220

Liu, 2016, Cul3-KLHL20 ubiquitin ligase governs the turnover of ULK1 and VPS34 complexes to control autophagy termination, Mol. Cell, 61, 84, 10.1016/j.molcel.2015.11.001

Lou, 2015, Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis, J. Med. Chem., 58, 512, 10.1021/jm500305p

Lu, 2014, The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins, Science, 343, 305, 10.1126/science.1244917

Lu, 2015, Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4, Chem. Biol., 22, 755, 10.1016/j.chembiol.2015.05.009

Matyskiela, 2016, A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase, Nature, 535, 252, 10.1038/nature18611

McAlister, 2014, MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes, Anal. Chem., 86, 7150, 10.1021/ac502040v

Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2

Nguyen, 2005, Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property, Mol. Cell. Biol., 25, 4977, 10.1128/MCB.25.12.4977-4992.2005

Nomanbhoy, 2016, Chemoproteomic evaluation of target engagement by the cyclin-dependent kinase 4 and 6 inhibitor palbociclib correlates with cancer cell response, Biochemistry, 55, 5434, 10.1021/acs.biochem.6b00629

Orning, 1991, Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes, J. Biol. Chem., 266, 1375, 10.1016/S0021-9258(18)52303-6

Patricelli, 2011, In situ kinase profiling reveals functionally relevant properties of native kinases, Chem. Biol., 18, 699, 10.1016/j.chembiol.2011.04.011

Patricelli, 2007, Functional interrogation of the kinome using nucleotide acyl phosphates, Biochemistry, 46, 350, 10.1021/bi062142x

Quentmeier, 2003, FLT3 mutations in acute myeloid leukemia cell lines, Leukemia, 17, 120, 10.1038/sj.leu.2402740

R Core Team, 2016

Raina, 2016, PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer, Proc. Natl. Acad. Sci. USA, 113, 7124, 10.1073/pnas.1521738113

Ran, 2013, Genome engineering using the CRISPR-Cas9 system, Nat. Protoc., 8, 2281, 10.1038/nprot.2013.143

Reiner, 2003, Identifying differentially expressed genes using false discovery rate controlling procedures, Bioinformatics, 19, 368, 10.1093/bioinformatics/btf877

Remillard, 2017, Degradation of the BAF complex factor BRD9 by heterobifunctional ligands, Angew. Chem. Int. Ed., 56, 5738, 10.1002/anie.201611281

Remsing Rix, 2009, Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells, Leukemia, 23, 477, 10.1038/leu.2008.334

Ritchie, 2015, limma powers differential expression analyses for RNA-sequencing and microarray studies, Nucleic Acids Res., 43, e47, 10.1093/nar/gkv007

Sakamoto, 2001, Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation, Proc. Natl. Acad. Sci. USA, 98, 8554, 10.1073/pnas.141230798

Schneekloth, 2008, Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics, Bioorg. Med. Chem. Lett., 18, 5904, 10.1016/j.bmcl.2008.07.114

Sekine, 2008, Small molecules destabilize cIAP1 by activating auto-ubiquitylation, J. Biol. Chem., 283, 8961, 10.1074/jbc.M709525200

Smith, 2012, Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia, Nature, 485, 260, 10.1038/nature11016

Taguchi, 2002, Degradation of human Aurora-A protein kinase is mediated by hCdh1, FEBS Lett., 519, 59, 10.1016/S0014-5793(02)02711-4

Umezawa, 1976, Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes, J. Antibiot. (Tokyo), 29, 97, 10.7164/antibiotics.29.97

Wander, 2014, The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond, Ther. Adv. Hematol., 5, 65, 10.1177/2040620714532123

Watanabe, 2004, M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP, Proc. Natl. Acad. Sci. USA, 101, 4419, 10.1073/pnas.0307700101

Weisberg, 2002, Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412, Cancer Cell, 1, 433, 10.1016/S1535-6108(02)00069-7

Weisberg, 2011, Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells, PLoS One, 6, e25351, 10.1371/journal.pone.0025351

Winter, 2015, Phthalimide conjugation as a strategy for in vivo target protein degradation, Science, 348, 1376, 10.1126/science.aab1433

Wu, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol. Sci., 36, 422, 10.1016/j.tips.2015.04.005

Zarrinkar, 2009, AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML), Blood, 114, 2984, 10.1182/blood-2009-05-222034

Zengerle, 2015, Selective small molecule induced degradation of the BET bromodomain protein BRD4, ACS Chem. Biol., 10, 1770, 10.1021/acschembio.5b00216

Zimmerman, 2013, Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia, Blood, 122, 3607, 10.1182/blood-2013-07-513044